This isotope will enable Isotopia’s production of Terbium-161 (Tb-161), a medical isotope reportedly showing promise for use in radiotherapeutics, including therapies targeting prostate and ...

Tb-161 offers a potential advantage over Lu-177 due to its emission of Auger electrons, which are highly effective in ...

(Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales. For Massachusetts ...